Aim and objectives: To investigate the rapport between the level of thyroid function, through blood level of TSH, both at onset, and in evolution and the level of antithyroperoxydase antibodies (ATPO) and antithyroglobuline antibodies (ATG) in Hashimoto thyroiditis and related diseases.
Material and method: Diagnosis: a. ATPO >34 μ/ml = Hashimoto thyroiditis (HT); b. ATPO=normal with high ATG = thyroiditis with only hyper-ATG (T-ATG); c. hypothyroidism without high ATPO/ATG = idiopathic mixedema (IM). 2. Thyroid function: TSH (and FT4) 3. Statistical analysis: linear correlation test.
Results: I. ATPO/ATG at onset: 1. ATPO: A. Number: HT-1092, T-ATG-61, IM-70. B. Average: TH-651,25; SD: 1055 (!); T-ATG-9,1; IM-10. 2. ATG in T-ATG: 539,81; SD: 940 (!).
II. Evolutional types for ATPO/ATG: 1. All ATPO in HT: no.1812, av: 662 μi/ml. 2. ATPO evolution in HT: undulatorious: 142 (41.4%), decreasing: 132 (38,5%), increasing: 69 (20.1%). 3. All ATG in T-ATG: no. 83, av: 494. 4. ATG in T-ATG: undulatorious: 2 (11.76%), decreasing: 9 (52.94%), increasing: 6 (35.29%).
III. TSH. 1. onset HT: av: 9.05 mU/l; S.D. 20.7. 2. onset T-ATG: 4.02 mU/l, S.D.=4.33. 3. All HT: av. 7.43.
IV. Linear correlation ATPO-TSH: 1. in HT: a. HT at onset: r=0.17, P<0.001, slope: 8.31. b. all TH values: r=0.11, P<0.001; 2. in T-ATG: a. at onset: r=−0.19, P>>0.1 (NS), slope: −35; b. all T-ATG values: r=−0.17, NS; c. MI at onset/and all values, r=−0.12, P>>0.1.
V. Linear correlation ATPO-FT4: 1. HT at onset: r: −0.11, P<0.001, slope: −9.32. 2. T-ATG at onset: r=0.001, NS.
Conclusion: 1 A certain correlation is: between thyroid function and only ATPO (not ATG) and only in cohorts (4001000 probes). 2. ATPO evolve unpredictably: high levels of ATPO occur in hypothyroidism, euthyroidism and hyperthyroidism, too.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
05 - 09 May 2012
European Society of Endocrinology